Instantaneous Tumor Spray for Real-Time Surgical Guidance
用于实时手术指导的瞬时肿瘤喷雾
基本信息
- 批准号:10681383
- 负责人:
- 金额:$ 99.94万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-01 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:Adjuvant ChemotherapyAdvanced Malignant NeoplasmBiodistributionBiological ProductsBiopsyBulky DiseaseCancer PatientCancer cell lineCancerousChemistryClinicalClinical ResearchCollaborationsCyclic GMPDataDetectionDevelopmentDiagnostic Neoplasm StagingDiseaseDoseDrug KineticsDyesEarly DiagnosisEndoscopyEvaluationExcisionEyeFeasibility StudiesFemaleFluorescenceFluorescent DyesFormulationFreeze DryingHumanImageIn VitroIntra-abdominalInvestigational DrugsLesionLettersLightMalignant Female Reproductive System NeoplasmMalignant NeoplasmsMalignant neoplasm of ovaryMeta-AnalysisMethodsModelingMolecular TargetMusNear-infrared optical imagingNeoadjuvant TherapyNeoplasm MetastasisNormal tissue morphologyOperative Surgical ProceduresOutcomePalpationPatient-Focused OutcomesPatientsPeritonealPharmaceutical PreparationsPhasePlatinumPrior ChemotherapyProceduresRattusRecurrenceRecurrent diseaseRecurrent tumorResectedResidual NeoplasmSecond Look SurgerySensitivity and SpecificitySerousSmall Business Innovation Research GrantSolidStainsSurgeonSurgical OncologyTechniquesTechnologyTimeTissuesToxic effectToxicologyTranslatingTumor DebulkingValidationVial deviceVisualVisualizationWomancancer surgerychemotherapeutic agentchemotherapyexperiencefirst-in-humanhuman studyimage guidedimaging modalityimprovedimproved outcomein vivo Modelintraperitonealmanufacturemedical schoolsmouse modelnovelpersonalized medicinepre-clinicalprognostic indicatorreal-time imagesscale upstandard of caresubcutaneoussurgery outcometargeted treatmenttooltumor
项目摘要
Early stage ovarian cancer is typically asymptomatic. Undiagnosed until the disease has reached an
advanced stage, the disease presents extensive intra-abdominal peritoneal metastases.
Standard of care treatment includes either a surgical cytoreduction to remove tumor bulk, then platinum-based
chemotherapy or primary neoadjuvant chemotherapy followed by interval cytoreduction after tumor shrinkage.
Despite successful initial treatments, 80–90% of women with advanced cancer experience tumor recurrence.
Surgical outcomes can vary considerably since some cancerous lesions are not visible to naked-eye
surveillance or palpation, the only tools available to the surgeon in real-time. There is significant evidence that
an extended disease-free period or even a cure are causally related to how much cancerous tissue is excised.
A sensitive, specific, easy to visualize dye which precisely highlights small (< 5mm) and otherwise hidden
lesions would better differentiate healthy from cancerous tissue, enable better informed surgical decisions and
lead to better outcomes for ovarian cancer patients.
In this collaboration between Molecular Targeting Technologies, Inc. and Weill Cornell Medical School we are
developing a novel, tumor-specific agent for intraoperative near-infrared fluorescence imaging to guide ovarian
cancer surgeries in real-time. In preliminary feasibility studies we have identified an optimized pH-sensitive
near-infrared fluorogenic dye (CypH-11) which is non-fluorescent in normal tissues, but fluoresces immediately
when sprayed onto cancer tissue, whose microenvironment is slightly acidic. We hypothesize that the cancer
selective staining by CypH-11 will make the surgical debulking procedure precise and effective by locating
normally unseen small and occult lesions, achieving a better surgical outcome. This approach could herald a
paradigm shift in surgical oncology.
In direct to Phase II SBIR studies we will scale-up synthesis and manufacture of CypH-11 and the final
formulated vial in compliance with cGMP; perform preclinical optimization and validation of the CypH-11
formulation in a subcutaneous murine model and validate its sensitivity and specificity in an orthotopic model
that simulates the clinical setting; and obtain pharmacokinetic, biodistribution and toxicity data to support an
exploratory IND filing. The application will be submitted to the FDA anticipating a Phase 0 first-in-human study.
早期卵巢癌通常是无症状的。直到疾病发展到晚期才被诊断出来
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Brian David Gray其他文献
Brian David Gray的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Brian David Gray', 18)}}的其他基金
Phosphatidylserine-blocking nanoparticles as improved anti-thrombotic with reduced bleeding risk
磷脂酰丝氨酸阻断纳米颗粒可改善抗血栓形成并降低出血风险
- 批准号:
10598788 - 财政年份:2023
- 资助金额:
$ 99.94万 - 项目类别:
Instantaneous Tumor Spray for Real-Time Surgical Guidance
用于实时手术指导的瞬时肿瘤喷雾
- 批准号:
10543617 - 财政年份:2022
- 资助金额:
$ 99.94万 - 项目类别:
Topical Drug Treatment of Cutaneous Leishmaniasis
皮肤利什曼病的局部药物治疗
- 批准号:
9383791 - 财政年份:2017
- 资助金额:
$ 99.94万 - 项目类别:
Multicolor Cell Membrane Profiling For Development And Disease
发育和疾病的多色细胞膜分析
- 批准号:
8589954 - 财政年份:2013
- 资助金额:
$ 99.94万 - 项目类别:
Anionic Phospholipid-Selective PET/SPECT Agent for Infection Imaging
用于感染成像的阴离子磷脂选择性 PET/SPECT 试剂
- 批准号:
8250164 - 财政年份:2012
- 资助金额:
$ 99.94万 - 项目类别:
Dual Modality Labels for Macro and Micro Detection and Quantification of Stem Cel
用于干细胞宏观和微观检测及定量的双模态标签
- 批准号:
7909750 - 财政年份:2010
- 资助金额:
$ 99.94万 - 项目类别:
Radiohybridization Imaging of HER2 Oncogene to Detect Breast Cancer
HER2 癌基因放射杂交成像检测乳腺癌
- 批准号:
7681555 - 财政年份:2008
- 资助金额:
$ 99.94万 - 项目类别:
Radiohybridization Imaging of HER2 Oncogene to Detect Breast Cancer
HER2 癌基因放射杂交成像检测乳腺癌
- 批准号:
7536308 - 财政年份:2008
- 资助金额:
$ 99.94万 - 项目类别:
Optimizing Tracers For Multicolor Neuronal Profiling
优化多色神经元分析示踪剂
- 批准号:
7418498 - 财政年份:2004
- 资助金额:
$ 99.94万 - 项目类别: